

OFF-LABEL DRUG USE IN A SPANISH UNIVERSITY HOSPITAL

J. Mateo, V. Arocas, O. García, C. Muñoz, M. Almanchel, C. Ramírez, R. Olmos, J. Velasco, M.A. Fernández, A. De La Rubia
Virgen de la Arrixaca University Hospital, Murcia, Spain.

Purpose

To analyze which clinical units requested more often off-label drugs, treatments and indications they were used, and to establish the economic impact

Material and methods

Descriptive observational study from October 2009 to December 2012.


Requests submitted by physicians

Assessment reports developed by pharmacists


Hospital medical administration authorize or reject

Results

ATC Groups most petitioned



Clinical Units



- **Most petitioned drugs:**
 1. Bevacizumab 13,3%
 2. Rituximab 8,2%
- **Most petitioned indications:**
 1. Glioblastoma 7,8%
 2. Breast cancer 5,3%
- **Cost of authorized off-label drugs:**
 1. € 4.938.808
 2. € 7.340 median cost per patient
- **Unapproved treatments** would have meant an expenditure of €1,656,644

Conclusions

1. Treatments, indications and clinical units most requested corresponded to the field of oncology and haematology.
2. The authorized off-label drugs have had a high economic impact.
3. Unapproved treatments would have increased costs with a theoretically minimal health benefits.

Poster DI-063